Preclinical results

The value of an idea lies in the using of it ~ Thomas Edison

For more than a decade now, Hemera’s team has been studying and testing therapies for the regeneration of nervous tissue.

Over the last few years, 10 independent in vivo experiments were performed on 220 mice using a model of blunt spinal cord injury, generating scientifically robust and very promising data.

In a preclinical model of severe spinal cord injury, the administration of REMAST therapy was proven to promote the repair of damaged nervous tissue and reduce the negative effects induced by a spinal cord lesion, allowing for long-lasting functional improvement.

REMAST therapy’s


Pre-clinical studies have shown that the therapy:


Has a neurotrophic effect, that is, it stimulates the growth of nervous tissue and motor neurons


Has an anti-inflammatory action at the site of the injury


Remodels and reduces the scar that causes disruption of neuronal connections


Has a pro-angiogenic effect, that is, it promotes the ability to create new blood vessels

REMAST therapy’s safety profile

In a preclinical experimental context, this therapy has shown a high safety profile:


Autologous approach, that is, the therapeutic cells are derived from the patient himself


No genetic manipulation, just phenotype modification


Spontaneous reversal of the activated cell phenotype a few days after the treatment


No evidence of side effects in the preclinical setting, even with long-term monitoring

Stay informed on Hemera’s latest activities with our Newsletter.